Thomas Andrew Gaziano, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cardiovascular Diseases | 69 | 2024 | 15652 | 3.670 |
Why?
|
South Africa | 41 | 2023 | 1867 | 2.450 |
Why?
|
Hypertension | 35 | 2023 | 8626 | 2.430 |
Why?
|
Cost-Benefit Analysis | 32 | 2024 | 5526 | 2.040 |
Why?
|
Rheumatic Fever | 6 | 2014 | 73 | 1.750 |
Why?
|
Rural Population | 12 | 2021 | 2317 | 1.470 |
Why?
|
Developing Countries | 20 | 2017 | 2911 | 1.420 |
Why?
|
Quality-Adjusted Life Years | 13 | 2022 | 1737 | 1.360 |
Why?
|
Rural Health Services | 3 | 2017 | 393 | 1.310 |
Why?
|
Cost Savings | 6 | 2022 | 904 | 1.130 |
Why?
|
Diabetes Mellitus | 16 | 2022 | 5891 | 1.100 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 10 | 2021 | 3251 | 1.100 |
Why?
|
Primary Prevention | 5 | 2014 | 1187 | 0.990 |
Why?
|
Cost of Illness | 11 | 2020 | 1950 | 0.990 |
Why?
|
Dyslipidemias | 5 | 2017 | 869 | 0.970 |
Why?
|
Tetrazoles | 3 | 2023 | 920 | 0.960 |
Why?
|
Antihypertensive Agents | 10 | 2023 | 2033 | 0.950 |
Why?
|
Rheumatic Heart Disease | 4 | 2014 | 165 | 0.940 |
Why?
|
Sodium Chloride, Dietary | 6 | 2022 | 303 | 0.920 |
Why?
|
Nutrition Surveys | 10 | 2020 | 1741 | 0.910 |
Why?
|
Penicillins | 4 | 2014 | 404 | 0.850 |
Why?
|
Pharyngitis | 3 | 2014 | 221 | 0.850 |
Why?
|
Heart Failure | 11 | 2024 | 11840 | 0.790 |
Why?
|
Heart Murmurs | 2 | 2020 | 92 | 0.790 |
Why?
|
Neprilysin | 2 | 2023 | 484 | 0.740 |
Why?
|
Systolic Murmurs | 1 | 2020 | 2 | 0.720 |
Why?
|
Mitral Valve Stenosis | 3 | 2020 | 343 | 0.700 |
Why?
|
Urinalysis | 1 | 2022 | 368 | 0.690 |
Why?
|
Health Promotion | 8 | 2014 | 2208 | 0.640 |
Why?
|
Mass Screening | 7 | 2019 | 5446 | 0.640 |
Why?
|
Drug Combinations | 4 | 2022 | 2077 | 0.640 |
Why?
|
Disease Management | 6 | 2024 | 2535 | 0.640 |
Why?
|
Glucosides | 1 | 2024 | 531 | 0.630 |
Why?
|
Sodium, Dietary | 1 | 2022 | 426 | 0.630 |
Why?
|
Food Services | 1 | 2022 | 209 | 0.610 |
Why?
|
Secondary Prevention | 2 | 2019 | 1472 | 0.610 |
Why?
|
Cholesterol, LDL | 5 | 2023 | 2393 | 0.600 |
Why?
|
Risk Assessment | 19 | 2024 | 24282 | 0.600 |
Why?
|
Health Care Costs | 8 | 2020 | 3242 | 0.590 |
Why?
|
Motivation | 3 | 2019 | 2018 | 0.570 |
Why?
|
Blood Pressure | 12 | 2023 | 8532 | 0.570 |
Why?
|
Budgets | 1 | 2019 | 232 | 0.560 |
Why?
|
Stroke Volume | 8 | 2024 | 5596 | 0.550 |
Why?
|
Streptococcus pyogenes | 3 | 2014 | 295 | 0.540 |
Why?
|
Dietary Sucrose | 1 | 2018 | 241 | 0.540 |
Why?
|
Regional Medical Programs | 2 | 2014 | 64 | 0.530 |
Why?
|
Taxes | 1 | 2018 | 219 | 0.530 |
Why?
|
Physical Fitness | 2 | 2011 | 742 | 0.510 |
Why?
|
Humans | 135 | 2024 | 765968 | 0.500 |
Why?
|
Aged | 58 | 2024 | 171117 | 0.490 |
Why?
|
Risk Factors | 41 | 2024 | 74840 | 0.480 |
Why?
|
Hyperlipidemias | 2 | 2018 | 770 | 0.480 |
Why?
|
Enalapril | 1 | 2016 | 317 | 0.460 |
Why?
|
Models, Economic | 5 | 2018 | 716 | 0.460 |
Why?
|
Middle Aged | 64 | 2024 | 223009 | 0.450 |
Why?
|
Argentina | 5 | 2023 | 249 | 0.440 |
Why?
|
Population Surveillance | 3 | 2017 | 2590 | 0.440 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 5 | 2023 | 1514 | 0.440 |
Why?
|
Chronic Disease | 8 | 2016 | 9347 | 0.440 |
Why?
|
Blood Chemical Analysis | 1 | 2015 | 433 | 0.440 |
Why?
|
Cholesterol, VLDL | 1 | 2013 | 70 | 0.430 |
Why?
|
Awareness | 2 | 2017 | 653 | 0.430 |
Why?
|
Prevalence | 18 | 2023 | 15842 | 0.430 |
Why?
|
Male | 75 | 2024 | 363698 | 0.420 |
Why?
|
Beverages | 1 | 2018 | 819 | 0.420 |
Why?
|
Female | 78 | 2024 | 396112 | 0.420 |
Why?
|
Patient Acceptance of Health Care | 3 | 2019 | 3230 | 0.410 |
Why?
|
Practice Guidelines as Topic | 12 | 2024 | 7425 | 0.400 |
Why?
|
Dyspnea | 1 | 2020 | 1352 | 0.400 |
Why?
|
Drug Costs | 3 | 2019 | 1193 | 0.400 |
Why?
|
Hyperaldosteronism | 1 | 2015 | 252 | 0.400 |
Why?
|
Streptococcal Infections | 2 | 2014 | 617 | 0.390 |
Why?
|
Hospitalization | 6 | 2022 | 10808 | 0.390 |
Why?
|
House Calls | 1 | 2014 | 171 | 0.390 |
Why?
|
Angiotensin Receptor Antagonists | 5 | 2023 | 1061 | 0.390 |
Why?
|
Adult | 57 | 2023 | 223044 | 0.380 |
Why?
|
Developed Countries | 3 | 2013 | 452 | 0.370 |
Why?
|
Renal Replacement Therapy | 1 | 2013 | 281 | 0.360 |
Why?
|
Coronary Disease | 5 | 2022 | 5912 | 0.360 |
Why?
|
Atherosclerosis | 3 | 2015 | 3424 | 0.360 |
Why?
|
Risk Reduction Behavior | 3 | 2019 | 1123 | 0.360 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 2 | 2017 | 254 | 0.360 |
Why?
|
Guatemala | 3 | 2015 | 161 | 0.350 |
Why?
|
India | 9 | 2018 | 2334 | 0.350 |
Why?
|
Cause of Death | 6 | 2017 | 3708 | 0.340 |
Why?
|
Smoking | 7 | 2016 | 9081 | 0.340 |
Why?
|
Health Knowledge, Attitudes, Practice | 4 | 2017 | 4058 | 0.330 |
Why?
|
Drug Resistance | 1 | 2015 | 1591 | 0.330 |
Why?
|
Longitudinal Studies | 11 | 2021 | 14751 | 0.320 |
Why?
|
Laboratories | 2 | 2021 | 462 | 0.320 |
Why?
|
Medication Adherence | 3 | 2019 | 2192 | 0.320 |
Why?
|
Telemedicine | 5 | 2024 | 3105 | 0.320 |
Why?
|
Life Style | 4 | 2017 | 3926 | 0.320 |
Why?
|
Cholesterol | 4 | 2021 | 2898 | 0.310 |
Why?
|
Decision Support Systems, Clinical | 2 | 2018 | 1175 | 0.310 |
Why?
|
Mexico | 3 | 2015 | 777 | 0.310 |
Why?
|
Medicare | 4 | 2024 | 6823 | 0.310 |
Why?
|
Health Priorities | 3 | 2017 | 382 | 0.300 |
Why?
|
Blood Transfusion | 1 | 2015 | 1297 | 0.300 |
Why?
|
Markov Chains | 5 | 2013 | 968 | 0.300 |
Why?
|
Diabetes Mellitus, Type 2 | 6 | 2024 | 12240 | 0.300 |
Why?
|
Cardiovascular System | 1 | 2015 | 841 | 0.300 |
Why?
|
Insurance Benefits | 1 | 2010 | 186 | 0.290 |
Why?
|
HIV Infections | 7 | 2021 | 17533 | 0.280 |
Why?
|
Interviews as Topic | 5 | 2018 | 2739 | 0.280 |
Why?
|
Insurance, Health | 4 | 2019 | 2521 | 0.280 |
Why?
|
Decision Support Techniques | 3 | 2022 | 2003 | 0.280 |
Why?
|
Urban Population | 3 | 2015 | 2040 | 0.280 |
Why?
|
Guidelines as Topic | 1 | 2013 | 1394 | 0.270 |
Why?
|
Cardiology | 3 | 2016 | 1702 | 0.270 |
Why?
|
Triglycerides | 2 | 2013 | 2441 | 0.270 |
Why?
|
Insurance Claim Review | 1 | 2011 | 746 | 0.270 |
Why?
|
Primary Health Care | 4 | 2019 | 4736 | 0.260 |
Why?
|
Stroke | 5 | 2022 | 9747 | 0.260 |
Why?
|
United States | 21 | 2024 | 72903 | 0.260 |
Why?
|
Socioeconomic Factors | 6 | 2018 | 7838 | 0.260 |
Why?
|
Drug Prescriptions | 1 | 2015 | 1662 | 0.260 |
Why?
|
Biphenyl Compounds | 3 | 2022 | 1019 | 0.250 |
Why?
|
Life Expectancy | 3 | 2019 | 1247 | 0.250 |
Why?
|
Patient Education as Topic | 2 | 2024 | 2334 | 0.250 |
Why?
|
Hypolipidemic Agents | 1 | 2009 | 608 | 0.240 |
Why?
|
Models, Theoretical | 2 | 2014 | 3564 | 0.240 |
Why?
|
Hospital Costs | 1 | 2011 | 956 | 0.240 |
Why?
|
Africa | 4 | 2016 | 725 | 0.230 |
Why?
|
Bangladesh | 3 | 2016 | 745 | 0.230 |
Why?
|
Kenya | 3 | 2016 | 758 | 0.230 |
Why?
|
Forecasting | 1 | 2013 | 2936 | 0.230 |
Why?
|
Referral and Consultation | 3 | 2018 | 3615 | 0.220 |
Why?
|
United Nations | 2 | 2016 | 151 | 0.220 |
Why?
|
Health Services Accessibility | 3 | 2019 | 5508 | 0.220 |
Why?
|
Hypercholesterolemia | 3 | 2023 | 1149 | 0.220 |
Why?
|
Aspirin | 3 | 2019 | 3134 | 0.220 |
Why?
|
Delivery of Health Care | 5 | 2023 | 5370 | 0.220 |
Why?
|
Quality of Life | 3 | 2020 | 13462 | 0.210 |
Why?
|
Angiotensins | 1 | 2023 | 139 | 0.210 |
Why?
|
Social Class | 2 | 2011 | 2007 | 0.210 |
Why?
|
Electrocardiography | 2 | 2021 | 6404 | 0.210 |
Why?
|
American Heart Association | 3 | 2017 | 1047 | 0.210 |
Why?
|
Community Health Services | 1 | 2007 | 657 | 0.200 |
Why?
|
Wounds and Injuries | 1 | 2015 | 2511 | 0.200 |
Why?
|
Health Care Rationing | 1 | 2005 | 436 | 0.200 |
Why?
|
Healthcare Disparities | 1 | 2017 | 3413 | 0.190 |
Why?
|
Cross-Sectional Studies | 15 | 2021 | 26318 | 0.190 |
Why?
|
International Cooperation | 3 | 2015 | 1432 | 0.190 |
Why?
|
Body Mass Index | 5 | 2017 | 13039 | 0.190 |
Why?
|
Registries | 2 | 2015 | 8297 | 0.190 |
Why?
|
Diet | 1 | 2019 | 8086 | 0.190 |
Why?
|
Decision Making | 1 | 2015 | 3965 | 0.180 |
Why?
|
Hospital Mortality | 1 | 2015 | 5343 | 0.180 |
Why?
|
Models, Biological | 2 | 2015 | 9443 | 0.180 |
Why?
|
Kidney Failure, Chronic | 1 | 2013 | 2495 | 0.180 |
Why?
|
Pakistan | 3 | 2016 | 300 | 0.180 |
Why?
|
Risk | 6 | 2019 | 9591 | 0.170 |
Why?
|
Emergency Medical Services | 2 | 2010 | 1938 | 0.170 |
Why?
|
Disease Outbreaks | 1 | 2010 | 1759 | 0.170 |
Why?
|
Morbidity | 2 | 2017 | 1749 | 0.170 |
Why?
|
Aged, 80 and over | 15 | 2022 | 59489 | 0.170 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2007 | 2268 | 0.170 |
Why?
|
Anti-Retroviral Agents | 3 | 2019 | 1787 | 0.160 |
Why?
|
Evidence-Based Medicine | 2 | 2010 | 3685 | 0.160 |
Why?
|
Clinical Competence | 1 | 2015 | 4863 | 0.160 |
Why?
|
Ventricular Function, Left | 2 | 2024 | 3928 | 0.160 |
Why?
|
Echocardiography | 3 | 2021 | 5045 | 0.160 |
Why?
|
South America | 2 | 2016 | 179 | 0.160 |
Why?
|
Atenolol | 1 | 2019 | 99 | 0.160 |
Why?
|
Ramipril | 1 | 2019 | 102 | 0.150 |
Why?
|
Potassium | 1 | 2022 | 1311 | 0.150 |
Why?
|
Comorbidity | 5 | 2019 | 10563 | 0.150 |
Why?
|
Mortality | 1 | 2009 | 2904 | 0.150 |
Why?
|
Blood Pressure Determination | 2 | 2023 | 647 | 0.140 |
Why?
|
Anti-Bacterial Agents | 2 | 2013 | 7478 | 0.140 |
Why?
|
Program Evaluation | 2 | 2017 | 2499 | 0.140 |
Why?
|
Physical Exertion | 1 | 2020 | 665 | 0.140 |
Why?
|
Sodium | 1 | 2022 | 1591 | 0.140 |
Why?
|
Autopsy | 2 | 2013 | 1011 | 0.140 |
Why?
|
Primary Care Nursing | 1 | 2016 | 1 | 0.140 |
Why?
|
China | 4 | 2016 | 2385 | 0.140 |
Why?
|
Acute Coronary Syndrome | 1 | 2010 | 2184 | 0.140 |
Why?
|
Benzhydryl Compounds | 1 | 2024 | 939 | 0.140 |
Why?
|
Adrenergic beta-Antagonists | 2 | 2021 | 1237 | 0.140 |
Why?
|
Oscillometry | 1 | 2017 | 151 | 0.130 |
Why?
|
Poverty | 4 | 2015 | 2714 | 0.130 |
Why?
|
Obesity | 4 | 2016 | 13076 | 0.130 |
Why?
|
Body Weights and Measures | 1 | 2017 | 208 | 0.130 |
Why?
|
Drug Therapy, Combination | 1 | 2006 | 6309 | 0.130 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2021 | 855 | 0.130 |
Why?
|
Lung Diseases | 2 | 2017 | 1940 | 0.130 |
Why?
|
Reminder Systems | 1 | 2019 | 388 | 0.130 |
Why?
|
Survival Analysis | 4 | 2022 | 10070 | 0.130 |
Why?
|
Workplace | 1 | 2022 | 873 | 0.120 |
Why?
|
Geography | 2 | 2018 | 652 | 0.120 |
Why?
|
Waist-Hip Ratio | 1 | 2017 | 520 | 0.120 |
Why?
|
Prehypertension | 1 | 2016 | 63 | 0.120 |
Why?
|
Depression | 4 | 2019 | 8237 | 0.120 |
Why?
|
ROC Curve | 2 | 2017 | 3620 | 0.120 |
Why?
|
Appointments and Schedules | 1 | 2019 | 444 | 0.120 |
Why?
|
Respiratory Tract Diseases | 2 | 2017 | 744 | 0.120 |
Why?
|
Age Factors | 5 | 2019 | 18380 | 0.120 |
Why?
|
Diabetes Complications | 3 | 2018 | 1316 | 0.120 |
Why?
|
Computer Simulation | 3 | 2020 | 6255 | 0.120 |
Why?
|
Hyperlipoproteinemia Type II | 1 | 2020 | 394 | 0.120 |
Why?
|
Sex Factors | 3 | 2018 | 10603 | 0.120 |
Why?
|
Renin-Angiotensin System | 1 | 2019 | 737 | 0.110 |
Why?
|
Comparative Effectiveness Research | 1 | 2019 | 714 | 0.110 |
Why?
|
Survival Rate | 3 | 2017 | 12795 | 0.110 |
Why?
|
Radiography, Thoracic | 1 | 2020 | 1315 | 0.110 |
Why?
|
Income | 2 | 2013 | 1874 | 0.110 |
Why?
|
Adrenalectomy | 1 | 2015 | 344 | 0.110 |
Why?
|
Medically Uninsured | 1 | 2019 | 838 | 0.110 |
Why?
|
Metabolic Diseases | 1 | 2019 | 687 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2023 | 10383 | 0.100 |
Why?
|
Hematologic Diseases | 1 | 2017 | 500 | 0.100 |
Why?
|
Obesity, Abdominal | 1 | 2016 | 369 | 0.100 |
Why?
|
Tomography, X-Ray Computed | 1 | 2015 | 20659 | 0.100 |
Why?
|
Lipid Metabolism | 1 | 2020 | 1892 | 0.100 |
Why?
|
Death Certificates | 1 | 2013 | 170 | 0.100 |
Why?
|
Urban Health Services | 1 | 2013 | 176 | 0.100 |
Why?
|
Cholesterol, HDL | 2 | 2016 | 1811 | 0.100 |
Why?
|
Probability | 1 | 2017 | 2475 | 0.090 |
Why?
|
Trans Fatty Acids | 1 | 2013 | 155 | 0.090 |
Why?
|
Glomerulonephritis | 1 | 2013 | 332 | 0.090 |
Why?
|
Continuity of Patient Care | 1 | 2018 | 1078 | 0.090 |
Why?
|
Time Factors | 6 | 2016 | 40065 | 0.090 |
Why?
|
Sex Distribution | 5 | 2007 | 2263 | 0.090 |
Why?
|
Predictive Value of Tests | 3 | 2015 | 15398 | 0.090 |
Why?
|
Emigrants and Immigrants | 1 | 2017 | 549 | 0.090 |
Why?
|
Models, Cardiovascular | 1 | 2016 | 978 | 0.090 |
Why?
|
Clinical Trials as Topic | 2 | 2024 | 8041 | 0.090 |
Why?
|
Age Distribution | 5 | 2007 | 2858 | 0.090 |
Why?
|
Incidence | 4 | 2021 | 21480 | 0.090 |
Why?
|
Cohort Studies | 7 | 2021 | 41649 | 0.080 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2024 | 2310 | 0.080 |
Why?
|
Treatment Failure | 1 | 2015 | 2652 | 0.080 |
Why?
|
Blood Glucose | 3 | 2021 | 6424 | 0.080 |
Why?
|
Arthralgia | 1 | 2013 | 459 | 0.080 |
Why?
|
Endocarditis | 1 | 2013 | 350 | 0.080 |
Why?
|
Preventive Health Services | 1 | 2013 | 570 | 0.080 |
Why?
|
Health Status | 1 | 2021 | 4080 | 0.070 |
Why?
|
Point-of-Care Systems | 1 | 2017 | 1217 | 0.070 |
Why?
|
Overweight | 2 | 2019 | 2444 | 0.070 |
Why?
|
Family Practice | 1 | 2010 | 508 | 0.070 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2019 | 2770 | 0.070 |
Why?
|
Urban Health | 2 | 2013 | 530 | 0.070 |
Why?
|
Self Report | 1 | 2018 | 3770 | 0.070 |
Why?
|
Epidemiologic Research Design | 1 | 2010 | 368 | 0.070 |
Why?
|
Mitral Valve Insufficiency | 2 | 2013 | 1414 | 0.070 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2010 | 791 | 0.070 |
Why?
|
Uruguay | 2 | 2016 | 104 | 0.060 |
Why?
|
Lipids | 1 | 2017 | 3315 | 0.060 |
Why?
|
Diagnostic Errors | 1 | 2013 | 1275 | 0.060 |
Why?
|
Medicaid | 1 | 2019 | 2833 | 0.060 |
Why?
|
Coronary Restenosis | 1 | 2008 | 396 | 0.060 |
Why?
|
Logistic Models | 4 | 2014 | 13266 | 0.060 |
Why?
|
Coronary Thrombosis | 1 | 2008 | 440 | 0.060 |
Why?
|
Algorithms | 5 | 2020 | 14071 | 0.060 |
Why?
|
Chile | 2 | 2016 | 258 | 0.060 |
Why?
|
C-Reactive Protein | 1 | 2017 | 3850 | 0.060 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 2 | 2017 | 326 | 0.060 |
Why?
|
Disease-Free Survival | 1 | 2015 | 6832 | 0.060 |
Why?
|
Sample Size | 2 | 2018 | 845 | 0.060 |
Why?
|
Europe, Eastern | 1 | 2024 | 72 | 0.060 |
Why?
|
History, 21st Century | 1 | 2010 | 1574 | 0.060 |
Why?
|
Treatment Outcome | 4 | 2024 | 65188 | 0.060 |
Why?
|
Follow-Up Studies | 5 | 2019 | 39193 | 0.050 |
Why?
|
Patient Selection | 1 | 2015 | 4255 | 0.050 |
Why?
|
Education, Medical | 1 | 2015 | 1746 | 0.050 |
Why?
|
Models, Statistical | 2 | 2019 | 5089 | 0.050 |
Why?
|
Software | 1 | 2017 | 4462 | 0.050 |
Why?
|
Peru | 2 | 2016 | 887 | 0.050 |
Why?
|
World Health Organization | 2 | 2021 | 1328 | 0.050 |
Why?
|
Multicenter Studies as Topic | 2 | 2018 | 1731 | 0.050 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2013 | 1566 | 0.050 |
Why?
|
History, 20th Century | 1 | 2010 | 2761 | 0.050 |
Why?
|
Cognition | 1 | 2019 | 7049 | 0.050 |
Why?
|
Longevity | 1 | 2010 | 1087 | 0.050 |
Why?
|
Drug-Eluting Stents | 1 | 2008 | 683 | 0.050 |
Why?
|
Aging | 2 | 2019 | 8731 | 0.050 |
Why?
|
Health Status Disparities | 1 | 2013 | 1880 | 0.050 |
Why?
|
Anti-HIV Agents | 1 | 2017 | 4559 | 0.050 |
Why?
|
Pharmacists | 1 | 2024 | 260 | 0.050 |
Why?
|
Diagnosis, Differential | 2 | 2013 | 12976 | 0.050 |
Why?
|
Receptors, Angiotensin | 1 | 2021 | 141 | 0.040 |
Why?
|
Income Tax | 1 | 2020 | 25 | 0.040 |
Why?
|
Residence Characteristics | 1 | 2010 | 2116 | 0.040 |
Why?
|
Biomedical Research | 1 | 2015 | 3458 | 0.040 |
Why?
|
Health Behavior | 2 | 2009 | 2650 | 0.040 |
Why?
|
Adolescent | 6 | 2018 | 88835 | 0.040 |
Why?
|
Linear Models | 1 | 2009 | 5876 | 0.040 |
Why?
|
Myocardial Infarction | 2 | 2016 | 11499 | 0.040 |
Why?
|
Research Design | 3 | 2019 | 6209 | 0.040 |
Why?
|
Data Collection | 2 | 2018 | 3318 | 0.040 |
Why?
|
Focus Groups | 2 | 2015 | 1459 | 0.040 |
Why?
|
Health Status Indicators | 1 | 2004 | 966 | 0.040 |
Why?
|
Iran | 1 | 2021 | 761 | 0.040 |
Why?
|
Health Surveys | 2 | 2013 | 4056 | 0.040 |
Why?
|
Prospective Studies | 5 | 2022 | 54802 | 0.040 |
Why?
|
Kidney | 2 | 2024 | 7066 | 0.040 |
Why?
|
Retrospective Studies | 2 | 2020 | 81514 | 0.040 |
Why?
|
Selection Bias | 1 | 2019 | 361 | 0.040 |
Why?
|
Child | 3 | 2017 | 80564 | 0.030 |
Why?
|
Health Resources | 1 | 2003 | 949 | 0.030 |
Why?
|
Europe | 1 | 2024 | 3423 | 0.030 |
Why?
|
Mendelian Randomization Analysis | 1 | 2022 | 1044 | 0.030 |
Why?
|
Exercise | 1 | 2013 | 5937 | 0.030 |
Why?
|
Public Policy | 1 | 2020 | 551 | 0.030 |
Why?
|
Coronary Artery Disease | 1 | 2015 | 6544 | 0.030 |
Why?
|
Surgical Attire | 1 | 2015 | 5 | 0.030 |
Why?
|
Infant | 1 | 2017 | 36386 | 0.030 |
Why?
|
Health Policy | 1 | 2008 | 2698 | 0.030 |
Why?
|
Public-Private Sector Partnerships | 1 | 2016 | 123 | 0.030 |
Why?
|
Fasting | 1 | 2021 | 1606 | 0.030 |
Why?
|
Asia | 1 | 2016 | 628 | 0.030 |
Why?
|
Brazil | 1 | 2018 | 1248 | 0.030 |
Why?
|
Antistreptolysin | 1 | 2013 | 6 | 0.030 |
Why?
|
Guideline Adherence | 1 | 2024 | 2243 | 0.030 |
Why?
|
Young Adult | 4 | 2016 | 59889 | 0.030 |
Why?
|
Alcohol Drinking | 2 | 2011 | 4040 | 0.030 |
Why?
|
Waist Circumference | 1 | 2016 | 932 | 0.020 |
Why?
|
Cultural Competency | 1 | 2015 | 303 | 0.020 |
Why?
|
Odds Ratio | 2 | 2014 | 9649 | 0.020 |
Why?
|
Hypoglycemic Agents | 1 | 2024 | 3110 | 0.020 |
Why?
|
Proportional Hazards Models | 2 | 2022 | 12509 | 0.020 |
Why?
|
Diffusion of Innovation | 1 | 2015 | 721 | 0.020 |
Why?
|
Research Personnel | 1 | 2015 | 590 | 0.020 |
Why?
|
Mice | 1 | 2017 | 81819 | 0.020 |
Why?
|
Pulmonary Edema | 1 | 2013 | 412 | 0.020 |
Why?
|
Caribbean Region | 1 | 2010 | 193 | 0.020 |
Why?
|
Interdisciplinary Communication | 1 | 2016 | 932 | 0.020 |
Why?
|
Child, Preschool | 1 | 2013 | 42500 | 0.020 |
Why?
|
Counseling | 1 | 2018 | 1551 | 0.020 |
Why?
|
Mentors | 1 | 2015 | 671 | 0.020 |
Why?
|
Viral Load | 1 | 2019 | 3386 | 0.020 |
Why?
|
Schools | 1 | 2018 | 1492 | 0.020 |
Why?
|
Ambulatory Care Facilities | 1 | 2015 | 939 | 0.020 |
Why?
|
Latin America | 1 | 2010 | 416 | 0.020 |
Why?
|
Leukocyte Count | 1 | 2013 | 1602 | 0.020 |
Why?
|
Regression Analysis | 1 | 2018 | 6322 | 0.020 |
Why?
|
Clinical Laboratory Techniques | 1 | 2014 | 747 | 0.020 |
Why?
|
Patient Discharge | 1 | 2022 | 3461 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2013 | 12056 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2007 | 15880 | 0.020 |
Why?
|
Program Development | 1 | 2015 | 1295 | 0.020 |
Why?
|
Educational Status | 1 | 2016 | 2513 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 2018 | 2686 | 0.020 |
Why?
|
Interpersonal Relations | 1 | 2015 | 1432 | 0.020 |
Why?
|
Communicable Diseases | 1 | 2015 | 874 | 0.020 |
Why?
|
Population Dynamics | 1 | 2009 | 314 | 0.020 |
Why?
|
Public Health | 1 | 2020 | 2680 | 0.020 |
Why?
|
Tanzania | 1 | 2011 | 1407 | 0.020 |
Why?
|
Demography | 1 | 2011 | 1641 | 0.020 |
Why?
|
Fatigue | 1 | 2013 | 1549 | 0.020 |
Why?
|
Fever | 1 | 2013 | 1603 | 0.020 |
Why?
|
Animals | 1 | 2017 | 168764 | 0.020 |
Why?
|
Atrial Fibrillation | 1 | 2003 | 5189 | 0.010 |
Why?
|
Qualitative Research | 1 | 2015 | 3139 | 0.010 |
Why?
|
Health Care Surveys | 1 | 2011 | 2424 | 0.010 |
Why?
|
Heart Diseases | 1 | 2016 | 2821 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2020 | 22223 | 0.010 |
Why?
|
Pharmaceutical Preparations | 1 | 2011 | 1084 | 0.010 |
Why?
|
Acute Disease | 1 | 2013 | 7232 | 0.010 |
Why?
|
HIV-1 | 1 | 2019 | 6944 | 0.010 |
Why?
|
Angioplasty, Balloon, Coronary | 1 | 2008 | 1727 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8703 | 0.010 |
Why?
|
Pilot Projects | 1 | 2014 | 8733 | 0.010 |
Why?
|
Feeding Behavior | 1 | 2011 | 3212 | 0.010 |
Why?
|
Health Expenditures | 1 | 2011 | 2387 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2016 | 26346 | 0.010 |
Why?
|
Prognosis | 1 | 2016 | 29922 | 0.010 |
Why?
|
Neoplasms | 1 | 2000 | 22340 | 0.000 |
Why?
|